Companies › Wave Life Sciences USA
3 active drug programs in 3 registered trials: 3 Phase 1; Metabolic and endocrine, Neurology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| WVE-N531 Antisense oligonucleotide (ASO) targeting exon 53 skipping in DMD | DMD | Phase 1 | Duchenne Muscular Dystrophy | Apr 2027 |
| WVE-006 RNA editing oligonucleotide to correct alpha-1 antitrypsin deficiency | SERPINA1 | Phase 1 | Alpha-1 Antitrypsin Deficiency | Sep 2027 |
| WVE-007 Stereopure siRNA oligonucleotide | – | Phase 1 | Overweight and Obesity | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04906460 | WVE-N531 | Phase 1 | Duchenne Muscular Dystrophy | Neurology | Apr 2027 |
| NCT06405633 | WVE-006 | Phase 1 | Alpha-1 Antitrypsin Deficiency | Metabolic and endocrine | Sep 2027 |
| NCT06842186 | WVE-007 | Phase 1 | Overweight and Obesity | Metabolic and endocrine | Dec 2027 |
Cash and short-term investments of $431m on 2026-09-30; operating cash outflow about $233m a year; runway about 22 months at that burn, to Aug 2028
Press releases filed as 8-K in the last year:
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.